A novel therapy for atopic dermatitis with allergen-antibody complexes: a double-blind, placebo-controlled study.
(1993) Journal of the American academy of dermatology — Vol. 28, n° 2 Pt 1, p. 232-239 (1993)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- BACKGROUND: Exposure to airborne allergens exacerbates symptoms of atopic dermatitis (AD) in hypersensitive patients. OBJECTIVE: Our purpose was to determine whether the administration of allergen-antibody complexes would improve the symptoms of AD. METHODS: Twenty-four adults with AD and hypersensitivity to Dermatophagoides pteronyssinus (Dpt) were treated in a double-blind, placebo-controlled trial by intradermal injections of complexes containing autologous specific antibodies and Dpt allergens. After 4 months, placebo-treated patients started receiving active treatment. All patients were treated for a full year. Clinical status and Dpt-specific IgG and IgE antibody levels were monitored. RESULTS: Symptoms of AD subsided within a few weeks after starting therapy, with significant reduction after 4 months in treated patients only. After 1 year, 82% of the patients exhibited a mean improvement of 83%, associated with reduction of Dpt-specific IgG antibodies. CONCLUSION: The treatment of Dpt-sensitive patients with AD by injections of allergen-antibody complexes is safe and effective in a majority of patients.
- Affiliations
Citations
Leroy, B. P., Boden, G., Lachapelle, J.-M., Jacquemin, M.-A., & Saint-Remy, J. M. (1993). A novel therapy for atopic dermatitis with allergen-antibody complexes: a double-blind, placebo-controlled study. Journal of the American academy of dermatology, 28(2 Pt 1), 232-239. https://doi.org/10.1016/0190-9622(93)70033-P (Original work published 1993)